Camino Minerals Corp
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- 46K
- Market Cap
- -
- Introduction
Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment focuses on the distribution of specialty, brand-name, and generic pharmaceuticals. The International Healthcare Solutions segment includes pharmaceutical wholesale, related operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.
Outlook Therapeutics Launches First Approved Ophthalmic Bevacizumab in Europe for Wet AMD Treatment
Outlook Therapeutics has commercially launched LYTENAVAâ„¢ (bevacizumab gamma) in Germany and the UK, marking the first and only approved ophthalmic formulation of bevacizumab for wet AMD treatment in Europe.
Harrow Secures Five-Year Supply Agreement for TRIESENCE® and Initiates Development of Next-Generation Version
• Harrow has executed a five-year strategic supply and development agreement with the current contract manufacturing organization for TRIESENCE®, ensuring stable supply of the ocular corticosteroid. • The company has begun developing an enhanced version of TRIESENCE®, with plans to submit a new drug application (NDA) to the FDA by the end of 2027. • TRIESENCE® is FDA-approved for visualization during vitrectomy and treatment of ocular inflammatory conditions unresponsive to topical corticosteroids, addressing a product previously on the FDA's Drug Shortage List.
Allogeneic Cell Therapies Drive Demand for Advanced Cryogenic Logistics
The cell and gene therapy (CGT) sector is rapidly evolving, with allogeneic cell therapies representing 50% of Phase I cell therapy trials, indicating a significant shift in therapeutic modalities.
Novel Approaches Reshape Rare Disease Drug Development: Experts Outline Path to Success
Experts highlight the growing acceptance of non-interventional and observational studies in rare disease research, with regulators showing increased flexibility for orphan drug development pathways.
Outlook Therapeutics Advances ONS-5010 Toward Potential First Approved Ophthalmic Bevacizumab for Retinal Diseases
Outlook Therapeutics received a positive opinion from the European Medicines Agency's CHMP for ONS-5010/LYTENAVAâ„¢ (bevacizumab gamma) for wet AMD treatment, with European Commission decision expected in Q2 2024.
US Biosimilar Market Set for $100 Billion Cost Reduction as Adoption Accelerates
The US biosimilar market has shown significant growth with 20 approved products, projected to reduce drug costs by $100 billion over the next five years through increased competition and adoption.
US Biosimilar Market Reaches Critical Milestone: Key Learnings from 5 Years of Growth
The US biosimilar market has evolved significantly since Sandoz's Zarxio launch five years ago, with six major biosimilar launches occurring in recent months and potential cost savings of $54 billion through 2026.